Advertisement

Picture Berlin Partner Bionnale 2021 Digital Event 650x80px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 3067 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 5 6 7 ... 29 30 31  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Centogene–FTI Consulting: public relations, 202004 service existent by FTI Consulting 2020-04-15
MOMA Therapeutics–Nextech: investment, 202004 financing round Series A totalling $86m incl co-investor Nextech Invest 2020-04-15
MOMA Therapeutics–SEVERAL: investment, 202004 financing round Series A $86m led by Third Rock Ventures 2020-04-15
Boehringer–Insilico Medicine: drug target discovery, 202004– collab research using machine learning + Pandomics Discovery Platform 2020-04-14
Roche–Arrakis Therapeutics: RNA-targeting drugs, 202004– collab strategic + license $190m upfront discovery of RNA-targeting small molecule drugs 2020-04-08
Takeda–Evotec: drug discovery services, 202004– collab multi-year €na gene therapy research alliance 2020-04-06
Evotec–PanCella: iPSC technology, 202004– license €na for use of iACT Stealth Cells + FailSafe technology with EVOcells platform 2020-04-02
PanCella–Evotec: investment, 202004 minority equity investment €na by Evotec in connection with license agreement 2020-04-02
Rgenta Therapeutics–Boehringer: investment, 202004 seed financing round totalling $20m incl co-lead investor BIVF 2020-04-02
Rgenta Therapeutics–SEVERAL: investment, 202004 seed financing round $20m co-led by BIVF + Matrix Partners China 2020-04-02
iTeos Therapeutics–SEVERAL: investment, 202004 financing round Series B2 $125m co-led by RA Capital Management + Boxer Capital 2020-04-01
Affinia Therapeutics–Lonza: AAV technology, 202003 license existent from Lonza + Massachusetts Eye and Ear 2020-03-31
Affinia Therapeutics–Lonza: investment, 202003 financing round Series A totalling $60m incl existing + co-investor Lonza 2020-03-31
Affinia Therapeutics–SEVERAL: investment, 202003 financing round Series A $60m co-led by Atlas Venture + F-Prime Capital + NEA 2020-03-31
Gilde Investment–SEVERAL: investment, 202003 first + final close of €416m Gilde Healthcare V fund incl investors Philips + Rabo Corp Investments 2020-03-31
Obi Medical–Roche: investment, 202003 acquisition of Obi Medical ApS by Roche 2020-03-31
Provirex–Hamburg (govt): investment, 202003 seed financing from Ascenion + Innovationsstarter Fonds Hamburg 2020-03-31
Provirex–Helmholtz: investment, 202003 seed financing from Ascenion + Innovationsstarter Fonds Hamburg 2020-03-31
SutroVax–Roche: investment, 202003 financing round Series D totalling $110m incl existing + co-investor Roche Venture Fund 2020-03-26
SutroVax–SEVERAL: investment, 202003 financing round Series D $110m co-led by new investors RA Capital + Janus Henderson 2020-03-26
Debiopharm–3B Pharmaceuticals: radiopharmaceutical, 202003– collab research + license ww excl for radioligand programme targeting CAIX enzyme 2020-03-25
Roche–Forge Therapeutics: antibiotics, 202003– collab research + license option up to $190.5m for FG-LpxC LUNG program for lung infections 2020-03-25
Immunogenesis–Minapharm: biopharma production, 202003– supply €na cell line + process developm + production of I-O-candidate by ProBiogen AG 2020-03-24
Bayer–Curadev: STING agonists, 202003– collab research + license agreem incl upfront payment + €250m milestones + single-digit royalties 2020-03-23
DeepSee project–Germany (govt): grant, 202003– funding from BMWi (ZIM) + Enterprise Singapore for single cell analysis for cancer drug r+d 2020-03-23
DeepSee project–Proteona: single cell analysis, 202003– collab project partner AI-driven multi-omics single cell analysis for cancer drug r+d 2020-03-23
DeepSee project–Singapore (govt): grant, 202003– funding from Enterprise Singapore + German BMWi for single cell analysis for cancer drug r+d 2020-03-23
DeepSee project–Synovo: single cell analysis, 202003– collab project partner AI-driven multi-omics single cell analysis for cancer drug r+d 2020-03-23
DeepSee project–Univ Tübingen: single cell analysis, 202003– collab NMI project partner AI-driven multi-omics single cell analysis for cancer drug r+d 2020-03-23
Koki Holdings–Eppendorf: investment, 202003– acquisition €na of Koki’s Centrifuge + Processing business by Eppendorf from KKR 2020-03-19
BMS–Oxford BioMedica: lentiviral vector technology, 202003– license non-excl + supply agreem LentiVector for CAR-T + TCR-T therapeutics of Juno 2020-03-18
OncoOne–SEVERAL: investment, 202003 financing round Series A €13m investors include FFG + AWS + two family offices 2020-03-18
OncoOne–Trophic Communications: public relations, 202003 service existent by Trophic Communications 2020-03-18
BioNTech–Pfizer: investment, 202003 equitiy investment $113m by Pfizer in connection with COVID-19 vaccine collaboration 2020-03-17
Immatics–Arya Sciences: investment, 202003 reverse merger resulting in Nasdaq-listing of Immatics + $148m cash held by Arya 2020-03-17
Immatics–SEVERAL: investment, 202003 common stock PIPE $104m led by Perceptive Advisors 2020-03-17
Pfizer–BioNTech: mRNA-based vaccines, 202003– collab $72m upfront + $563m milestones developm COVID-19 vaccine 2020-03-17
BioNTech–Fosun: investment, 202003 equity investment €44m for 1.58m ordinary shares by Fosun Pharma as part of COVID-19 vaccine collab 2020-03-16
Fosun–BioNTech: mRNA-based vaccines, 202003– collab up to €120m + profit sharing development of COVID-19 vaccine in China with Fosun Pharma 2020-03-16
NanoSyrinx–BioCity (GB): investment, 202003–202009 pre-seed financing round incl co-investor BioCity Group 2020-03-16
NanoSyrinx–Merck (DE): investment, 202003–202009 pre-seed financing round incl lead investor M Ventures 2020-03-16
NanoSyrinx–Midven: investment, 202003–202009 pre-seed financing round incl co-investor UKI2S Fund 2020-03-16
NanoSyrinx–SEVERAL: investment, 202003–202009 pre-seed financing round led by M Ventures + incl BioCity + UKI2S Fund 2020-03-16
Life Sciences Partners–BMS: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor BMS 2020-03-10
Life Sciences Partners–EU (govt): investment, 202003 final closing totalling €600m of LSP 6 fund incl investor EIF 2020-03-10
Life Sciences Partners–Otsuka: investment, 202003 final closing totalling €600m of LSP 6 fund incl investor Otsuka Pharmaceutical 2020-03-10
Life Sciences Partners–SEVERAL: investment, 202003 final closing €600m of LSP 6 fund with investors incl BMS + Otsuka + EIF 2020-03-10
Roche–Genedata: bioinformatics, 202003– supply Chugai Pharmaceutical implements Genedata Profiler for biomarker discovery + validation 2020-03-10
iAtros–Bavaria (govt): investment, 202003 seed financing round totalling €2m incl investor Bayern Kapital 2020-03-09
iAtros–High-Tech Gründerfonds: investment, 202003 seed financing round totalling €2m incl investor HTGF 2020-03-09
iAtros–OTHER: investment, 202003 seed financing round totalling €2m incl several business angels 2020-03-09
iAtros–SEVERAL: investment, 202003 seed financing round €2m from HTGF + Bayern Kapital + several business angels 2020-03-09
Numab–MacDougall Biomedical Communications: public relations, 202003 service existent by MacDougall 2020-03-09
Ubirch–SEVERAL: investment, 202003 third financing round seven-digit € amount led by hubraum Deutsche Telekom + NRW.BANK 2020-03-06
Qiagen–Barclays: financial services, 202003 supply service Barclays Bank plc is financial advisor w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–De Brauw Blackstone Westbroek: legal services, 202003 supply service De Brauw BW NV is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Goldman Sachs: financial services, 202003 supply service Goldman Sachs Intl is lead financial advisor w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Linklaters: legal services, 202003 supply service Linklaters LLP is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Mintz Levin Cohn: legal services, 202003 supply service Mintz Levin Cohn FGP is legal counsel w regard to acquisition by Thermo Fisher 2020-03-03
Qiagen–Thermo Fisher: investment, 202003–202008 acquisition €9.14b cash tender offer at €39/share later raised to €43 NOT ACCEPTED 2020-03-03
Thermo Fisher–JPMorgan Chase: financial services, 202003 supply service JP Morgan Securities LLC is financial advisor w regard to Qiagen acquisition 2020-03-03
Thermo Fisher–Morgan Stanley: financial services, 202003 supply service Morgan Stanley & Co LLC is financial advisor w regard to Qiagen acquisition 2020-03-03
Thermo Fisher–Wachtel Lipton Rosen & Katz: legal services, 202003 legal council to Thermo Fisher with regard to acquisition of Qiagen 2020-03-03
Sterling Pharma Solutions–Thermo Fisher: LC system, 202003 supply early customer for Vanquish Core HPLC System 2020-03-02
Digital Therapeutics–SEVERAL: investment, 202003 financing round Series A $11m of Digital Therapeutics Inc d/b/a Quit Genius 2020-03-01
Boehringer–Trutino Biosciences: cancer immunotherapy, 202002– collab research + ww excl license to develop up to 3 candidates using ODC technology 2020-02-27
Amgen–Genedata: bioinformatics, 202002 supply existent Amgen is existing customer of Genedata 2020-02-26
Centogene–Coulter Partners: recruitment services, 202002 supply service placement of Philip Lambert as CSO at Centogen based in US 2020-02-26
Genmab–Genedata: bioinformatics, 202002 supply existent Genmab is existing customer of Genedata 2020-02-26
Ipsen–Genedata: bioinformatics, 202002 supply existent Ipsen is existing customer of Genedata 2020-02-26
Lundbeck–Genedata: bioinformatics, 202002 supply existent Lundbeck is existing customer of Genedata 2020-02-26
Merus–Genedata: bioinformatics, 202002 supply existent Merus is existing customer of Genedata 2020-02-26
Novo Group–Genedata: bioinformatics, 202002 supply existent Novo Nordisk is existing customer of Genedata 2020-02-26
Novo Group–Genedata: bioinformatics, 202002 supply existent Novozymes is existing customer of Genedata 2020-02-26
Octapharma–Genedata: bioinformatics, 202002 supply existent Octapharma is existing customer of Genedata 2020-02-26
Servier–Genedata: bioinformatics, 202002 supply existent Servier is existing customer of Genedata 2020-02-26
Twist Bioscience–Genedata: bioinformatics, 202002 supply existent Twist is existing customer of Genedata 2020-02-26
FinnGen–GSK: genomics, 202002 collab existent GSK is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Merck (US): genomics, 202002 collab existent MSD is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Pfizer: genomics, 202002 collab existent Pfizer is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Roche: genomics, 202002 collab existent Genentech is industry partner of Finnish genome research project FinnGen 2020-02-25
FinnGen–Sanofi: genomics, 202002 collab existent Sanofi is industry partner of Finnish genome research project FinnGen 2020-02-25
ImmunOs Therapeutics–Minapharm: biopharma production, 202002– supply €na support developm using DirectedLuck + large-scale production by ProBioGen 2020-02-25
Peptilogics–CARB-X: grant, 202002– up to $12.17m CARB-X Award for developm of PLG0206 for PJI + peptide discovery platform 2020-02-25
Roche–Bicycle Therapeutics: small-molecule drugs, 202002– collab strategic $30m upfront + up to $1.7b r+d of bicycle peptides for cancer Genentech 2020-02-25
Scipio Bioscience–BPCE: investment, 202002 financing round Series A totalling €6m incl existing + co-investor Seventure Partners Quadrivium 1 Fund 2020-02-25
Scipio Bioscience–High-Tech Gründerfonds: investment, 202002 financing round Series A totalling €6m incl existing + co-investor HTGF 2020-02-25
Scipio Bioscience–Merck (DE): investment, 202002 financing round Series A totalling €6m incl lead investor M Ventures 2020-02-25
Scipio Bioscience–SEVERAL: investment, 202002 financing round Series A €6m led by M Ventures 2020-02-25
Scipio Bioscience–Verve Capital Partners: investment, 202002 financing round Series A totalling €6m incl new + co-investor investiere 2020-02-25
GSK–Immatics: cell therapy, 202002– strategic collab $45m upfront + $1.1b milestones for first two TCR therapeutics programmes + royalties 2020-02-20
Merck (DE)–Dermapharm: investment, 202002–202003 acquisition €na of Merck’s allergy business Allergopharma by Dermapharm Holding SE 2020-02-19
Boehringer–Carebox Healthcare Solutions: clinical research s/w, 202002– use of MyStudyWindow SaaS for global patient recruitment 2020-02-18
OncoDNA–SEVERAL: investment, 202002 financing round Series B €19m co-led by Vesalius Biocapital III + Swisscanto Invest 2020-02-14
OncoDNA–Vesalius Biocapital: investment, 202002 financing round Series B totalling €19m incl co-lead investor Vesalius Biocapital III 2020-02-14
OncoDNA–Zürcher Kantonalbank: investment, 202002 financing round Series B totalling €19m incl co-lead investor Swisscanto Invest by ZKB 2020-02-14
Biomes NGS–Yabeo Capital: investment, 202002 pre-series A investment €2m from Yabeo 2020-02-13
NanoPin Technologies–Thermo Fisher: mass spectrometry, 202002– collab developm LC-MS-based workflows for blood-based infectious disease diagnostics 2020-02-13
Azafaros–BioMedPartners: investment, 202002 financing round Series A totalling €25m incl co-investor BioMedPartners 2020-02-06
Azafaros–SEVERAL: investment, 202002 financing round Series A €25m led by Forbion with participation from BioMedPartners + BGV 2020-02-06
next pagenext page 1 2 3 ... 5 6 7 ... 29 30 31  next pagenext page



Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

» top